- Home
- TSHA vs KURA Comparison
TSHA vs KURA Comparison
Compare TSHA & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- KURA
- Stock Information
- Founded
- TSHA 2019
- KURA 2014
- Country
- TSHA United States
- KURA United States
- Employees
- TSHA N/A
- KURA N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TSHA Health Care
- KURA Health Care
- Exchange
- TSHA Nasdaq
- KURA Nasdaq
- Market Cap
- TSHA 1.2B
- KURA 1.0B
- IPO Year
- TSHA 2020
- KURA N/A
- Fundamental
- Price
- TSHA $4.87
- KURA $12.08
- Analyst Decision
- TSHA Strong Buy
- KURA Buy
- Analyst Count
- TSHA 9
- KURA 11
- Target Price
- TSHA $10.22
- KURA $25.00
- AVG Volume (30 Days)
- TSHA 3.9M
- KURA 2.2M
- Earning Date
- TSHA 11-04-2025
- KURA 11-04-2025
- Dividend Yield
- TSHA N/A
- KURA N/A
- EPS Growth
- TSHA N/A
- KURA N/A
- EPS
- TSHA N/A
- KURA N/A
- Revenue
- TSHA $6,310,000.00
- KURA $104,029,000.00
- Revenue This Year
- TSHA N/A
- KURA $68.63
- Revenue Next Year
- TSHA N/A
- KURA $141.59
- P/E Ratio
- TSHA N/A
- KURA N/A
- Revenue Growth
- TSHA N/A
- KURA N/A
- 52 Week Low
- TSHA $1.05
- KURA $5.41
- 52 Week High
- TSHA $5.51
- KURA $12.49
- Technical
- Relative Strength Index (RSI)
- TSHA 62.34
- KURA 66.94
- Support Level
- TSHA $3.92
- KURA $10.86
- Resistance Level
- TSHA $4.34
- KURA $11.88
- Average True Range (ATR)
- TSHA 0.30
- KURA 0.88
- MACD
- TSHA 0.06
- KURA 0.08
- Stochastic Oscillator
- TSHA 98.33
- KURA 85.86
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.